Skip to main content
NCBI home page
Molecular Pathology : MP logoLink to Molecular Pathology : MP
. 1998 Oct;51(5):248–253. doi: 10.1136/mp.51.5.248

Demystified ... p53.

S J Darnton 1
PMCID: PMC395647  PMID: 10193518

Full Text

The Full Text of this article is available as a PDF (169.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arends M. J., Buckley C. H., Wells M. Aetiology, pathogenesis, and pathology of cervical neoplasia. J Clin Pathol. 1998 Feb;51(2):96–103. doi: 10.1136/jcp.51.2.96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bissonnette N., Wasylyk B., Hunting D. J. The apoptotic and transcriptional transactivation activities of p53 can be dissociated. Biochem Cell Biol. 1997;75(4):351–358. [PubMed] [Google Scholar]
  3. Blount P. L., Meltzer S. J., Yin J., Huang Y., Krasna M. J., Reid B. J. Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma. Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3221–3225. doi: 10.1073/pnas.90.8.3221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brash D. E., Rudolph J. A., Simon J. A., Lin A., McKenna G. J., Baden H. P., Halperin A. J., Pontén J. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10124–10128. doi: 10.1073/pnas.88.22.10124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brennan J. A., Mao L., Hruban R. H., Boyle J. O., Eby Y. J., Koch W. M., Goodman S. N., Sidransky D. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med. 1995 Feb 16;332(7):429–435. doi: 10.1056/NEJM199502163320704. [DOI] [PubMed] [Google Scholar]
  6. Calzolari A., Chiarelli I., Bianchi S., Messerini L., Gallo O., Porfirio B., Mattiuz P. L. Immunohistochemical vs molecular biology methods. Complementary techniques for effective screening of p53 alterations in head and neck cancer. Am J Clin Pathol. 1997 Jan;107(1):7–11. doi: 10.1093/ajcp/107.1.7. [DOI] [PubMed] [Google Scholar]
  7. Cheung A. N., Shen D. H., Khoo U. S., Wong L. C., Ngan H. Y. p21WAF1/CIP1 expression in gestational trophoblastic disease: correlation with clinicopathological parameters, and Ki67 and p53 gene expression. J Clin Pathol. 1998 Feb;51(2):159–162. doi: 10.1136/jcp.51.2.159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cooper D. N., Krawczak M. The mutational spectrum of single base-pair substitutions causing human genetic disease: patterns and predictions. Hum Genet. 1990 Jun;85(1):55–74. doi: 10.1007/BF00276326. [DOI] [PubMed] [Google Scholar]
  9. Cox L. S. Multiple pathways control cell growth and transformation: overlapping and independent activities of p53 and p21Cip1/WAF1/Sdi1. J Pathol. 1997 Oct;183(2):134–140. doi: 10.1002/(SICI)1096-9896(199710)183:2<134::AID-PATH960>3.0.CO;2-D. [DOI] [PubMed] [Google Scholar]
  10. Dameron K. M., Volpert O. V., Tainsky M. A., Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 1994 Sep 9;265(5178):1582–1584. doi: 10.1126/science.7521539. [DOI] [PubMed] [Google Scholar]
  11. Darnton S. J., Jenner K. Microwave irradiation lowers immunohistological detection thresholds for p53 protein in squamous epithelium from non-neoplastic oesophagus. J Pathol. 1998 Jul;185(3):334–335. doi: 10.1002/(SICI)1096-9896(199807)185:3<334::AID-PATH36>3.0.CO;2-0. [DOI] [PubMed] [Google Scholar]
  12. Donehower L. A., Harvey M., Slagle B. L., McArthur M. J., Montgomery C. A., Jr, Butel J. S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992 Mar 19;356(6366):215–221. doi: 10.1038/356215a0. [DOI] [PubMed] [Google Scholar]
  13. Dowell S. P., Ogden G. R. The use of antigen retrieval for immunohistochemical detection of p53 over-expression in malignant and benign oral mucosa: a cautionary note. J Oral Pathol Med. 1996 Feb;25(2):60–64. doi: 10.1111/j.1600-0714.1996.tb00193.x. [DOI] [PubMed] [Google Scholar]
  14. Fearon E. R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990 Jun 1;61(5):759–767. doi: 10.1016/0092-8674(90)90186-i. [DOI] [PubMed] [Google Scholar]
  15. Fields S., Jang S. K. Presence of a potent transcription activating sequence in the p53 protein. Science. 1990 Aug 31;249(4972):1046–1049. doi: 10.1126/science.2144363. [DOI] [PubMed] [Google Scholar]
  16. Fujiwara T., Grimm E. A., Mukhopadhyay T., Zhang W. W., Owen-Schaub L. B., Roth J. A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 1994 May 1;54(9):2287–2291. [PubMed] [Google Scholar]
  17. Gannon J. V., Greaves R., Iggo R., Lane D. P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 1990 May;9(5):1595–1602. doi: 10.1002/j.1460-2075.1990.tb08279.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Greenblatt M. S., Bennett W. P., Hollstein M., Harris C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994 Sep 15;54(18):4855–4878. [PubMed] [Google Scholar]
  19. Hainaut P., Hernandez T., Robinson A., Rodriguez-Tome P., Flores T., Hollstein M., Harris C. C., Montesano R. IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res. 1998 Jan 1;26(1):205–213. doi: 10.1093/nar/26.1.205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Harper J. W., Adami G. R., Wei N., Keyomarsi K., Elledge S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993 Nov 19;75(4):805–816. doi: 10.1016/0092-8674(93)90499-g. [DOI] [PubMed] [Google Scholar]
  21. Harris C. C., Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 1993 Oct 28;329(18):1318–1327. doi: 10.1056/NEJM199310283291807. [DOI] [PubMed] [Google Scholar]
  22. Hinds P. W., Finlay C. A., Quartin R. S., Baker S. J., Fearon E. R., Vogelstein B., Levine A. J. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ. 1990 Dec;1(12):571–580. [PubMed] [Google Scholar]
  23. Hollstein M. C., Metcalf R. A., Welsh J. A., Montesano R., Harris C. C. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci U S A. 1990 Dec;87(24):9958–9961. doi: 10.1073/pnas.87.24.9958. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. doi: 10.1126/science.1905840. [DOI] [PubMed] [Google Scholar]
  25. Hruban R. H., van der Riet P., Erozan Y. S., Sidransky D. Brief report: molecular biology and the early detection of carcinoma of the bladder--the case of Hubert H. Humphrey. N Engl J Med. 1994 May 5;330(18):1276–1278. doi: 10.1056/NEJM199405053301805. [DOI] [PubMed] [Google Scholar]
  26. Häcker G., Vaux D. L. Apoptosis. A sticky business. Curr Biol. 1995 Jun 1;5(6):622–624. doi: 10.1016/s0960-9822(95)00126-6. [DOI] [PubMed] [Google Scholar]
  27. Jayaraman J., Prives C. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell. 1995 Jun 30;81(7):1021–1029. doi: 10.1016/s0092-8674(05)80007-8. [DOI] [PubMed] [Google Scholar]
  28. Kern S. E., Kinzler K. W., Bruskin A., Jarosz D., Friedman P., Prives C., Vogelstein B. Identification of p53 as a sequence-specific DNA-binding protein. Science. 1991 Jun 21;252(5013):1708–1711. doi: 10.1126/science.2047879. [DOI] [PubMed] [Google Scholar]
  29. Kraiss S., Quaiser A., Oren M., Montenarh M. Oligomerization of oncoprotein p53. J Virol. 1988 Dec;62(12):4737–4744. doi: 10.1128/jvi.62.12.4737-4744.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Kushner J., Bradley G., Jordan R. C. Patterns of p53 and Ki-67 protein expression in epithelial dysplasia from the floor of the mouth. J Pathol. 1997 Dec;183(4):418–423. doi: 10.1002/(SICI)1096-9896(199712)183:4<418::AID-PATH946>3.0.CO;2-T. [DOI] [PubMed] [Google Scholar]
  31. Lane D. P., Benchimol S. p53: oncogene or anti-oncogene? Genes Dev. 1990 Jan;4(1):1–8. doi: 10.1101/gad.4.1.1. [DOI] [PubMed] [Google Scholar]
  32. Lane D. P. Cancer. p53, guardian of the genome. Nature. 1992 Jul 2;358(6381):15–16. doi: 10.1038/358015a0. [DOI] [PubMed] [Google Scholar]
  33. Lavieille J. P., Lubin R., Soussi T., Reyt E., Brambilla C., Riva C. Analysis of p53 antibody response in patients with squamous cell carcinoma of the head and neck. Anticancer Res. 1996 Jul-Aug;16(4C):2385–2388. [PubMed] [Google Scholar]
  34. Mao L., Hruban R. H., Boyle J. O., Tockman M., Sidransky D. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res. 1994 Apr 1;54(7):1634–1637. [PubMed] [Google Scholar]
  35. McKee P. H., Hobbs C., Hall P. A. Antigen retrieval by microwave irradiation lowers immunohistological detection thresholds. Histopathology. 1993 Oct;23(4):377–379. doi: 10.1111/j.1365-2559.1993.tb01223.x. [DOI] [PubMed] [Google Scholar]
  36. Milner J., Medcalf E. A. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell. 1991 May 31;65(5):765–774. doi: 10.1016/0092-8674(91)90384-b. [DOI] [PubMed] [Google Scholar]
  37. Momand J., Zambetti G. P., Olson D. C., George D., Levine A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992 Jun 26;69(7):1237–1245. doi: 10.1016/0092-8674(92)90644-r. [DOI] [PubMed] [Google Scholar]
  38. Muzeau F., Fléjou J. F., Potet F., Belghiti J., Thomas G., Hamelin R. Profil des mutations du gène p53 et expression anormale de la protéine p53 dans les deux formes de cancer de l'oesophage. Gastroenterol Clin Biol. 1996;20(5):430–437. [PubMed] [Google Scholar]
  39. Nguyen K. T., Liu B., Ueda K., Gottesman M. M., Pastan I., Chin K. V. Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants. Oncol Res. 1994;6(2):71–77. [PubMed] [Google Scholar]
  40. Nowell P. C. The clonal evolution of tumor cell populations. Science. 1976 Oct 1;194(4260):23–28. doi: 10.1126/science.959840. [DOI] [PubMed] [Google Scholar]
  41. Orita M., Suzuki Y., Sekiya T., Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics. 1989 Nov;5(4):874–879. doi: 10.1016/0888-7543(89)90129-8. [DOI] [PubMed] [Google Scholar]
  42. Parker S. B., Eichele G., Zhang P., Rawls A., Sands A. T., Bradley A., Olson E. N., Harper J. W., Elledge S. J. p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science. 1995 Feb 17;267(5200):1024–1027. doi: 10.1126/science.7863329. [DOI] [PubMed] [Google Scholar]
  43. Peng H. Q., Hogg D., Malkin D., Bailey D., Gallie B. L., Bulbul M., Jewett M., Buchanan J., Goss P. E. Mutations of the p53 gene do not occur in testis cancer. Cancer Res. 1993 Aug 1;53(15):3574–3578. [PubMed] [Google Scholar]
  44. Peyrat J. P., Bonneterre J., Lubin R., Vanlemmens L., Fournier J., Soussi T. Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet. 1995 Mar 11;345(8950):621–622. doi: 10.1016/s0140-6736(95)90523-5. [DOI] [PubMed] [Google Scholar]
  45. Reid B. J., Sanchez C. A., Blount P. L., Levine D. S. Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology. 1993 Jul;105(1):119–129. doi: 10.1016/0016-5085(93)90017-7. [DOI] [PubMed] [Google Scholar]
  46. Roth J. A., Nguyen D., Lawrence D. D., Kemp B. L., Carrasco C. H., Ferson D. Z., Hong W. K., Komaki R., Lee J. J., Nesbitt J. C. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med. 1996 Sep;2(9):985–991. doi: 10.1038/nm0996-985. [DOI] [PubMed] [Google Scholar]
  47. Ruley H. E. p53 and response to chemotherapy and radiotherapy. Important Adv Oncol. 1996:37–56. [PubMed] [Google Scholar]
  48. Steller H. Mechanisms and genes of cellular suicide. Science. 1995 Mar 10;267(5203):1445–1449. doi: 10.1126/science.7878463. [DOI] [PubMed] [Google Scholar]
  49. Stephen C. W., Lane D. P. Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library. J Mol Biol. 1992 Jun 5;225(3):577–583. doi: 10.1016/0022-2836(92)90386-x. [DOI] [PubMed] [Google Scholar]
  50. Storey A., Thomas M., Kalita A., Harwood C., Gardiol D., Mantovani F., Breuer J., Leigh I. M., Matlashewski G., Banks L. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998 May 21;393(6682):229–234. doi: 10.1038/30400. [DOI] [PubMed] [Google Scholar]
  51. Tan T. H., Wallis J., Levine A. J. Identification of the p53 protein domain involved in formation of the simian virus 40 large T-antigen-p53 protein complex. J Virol. 1986 Sep;59(3):574–583. doi: 10.1128/jvi.59.3.574-583.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Tanaka H., Shibagaki I., Shimada Y., Wagata T., Imamura M., Ishizaki K. Characterization of p53 gene mutations in esophageal squamous cell carcinoma cell lines: increased frequency and different spectrum of mutations from primary tumors. Int J Cancer. 1996 Jan 26;65(3):372–376. doi: 10.1002/(SICI)1097-0215(19960126)65:3<372::AID-IJC16>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  53. Van Meir E. G., Polverini P. J., Chazin V. R., Su Huang H. J., de Tribolet N., Cavenee W. K. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet. 1994 Oct;8(2):171–176. doi: 10.1038/ng1094-171. [DOI] [PubMed] [Google Scholar]
  54. Vogelstein B., Kinzler K. W. p53 function and dysfunction. Cell. 1992 Aug 21;70(4):523–526. doi: 10.1016/0092-8674(92)90421-8. [DOI] [PubMed] [Google Scholar]
  55. Xiong Y., Hannon G. J., Zhang H., Casso D., Kobayashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 1993 Dec 16;366(6456):701–704. doi: 10.1038/366701a0. [DOI] [PubMed] [Google Scholar]
  56. Ziegler A., Jonason A. S., Leffell D. J., Simon J. A., Sharma H. W., Kimmelman J., Remington L., Jacks T., Brash D. E. Sunburn and p53 in the onset of skin cancer. Nature. 1994 Dec 22;372(6508):773–776. doi: 10.1038/372773a0. [DOI] [PubMed] [Google Scholar]
  57. el-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993 Nov 19;75(4):817–825. doi: 10.1016/0092-8674(93)90500-p. [DOI] [PubMed] [Google Scholar]

Articles from Molecular Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES